Quris is a disruptive BioAI machine-learning platform that better predicts which drug candidates will safely work in humans, and allows the efficient discovery of new drugs and the repurposing and personalization of existing drugs. It generates proprietary classified data by testing thousands of known drugs on genetically diverse miniaturized ‘patients-on-a-chip’ that are uniquely available to Quris, and is based on Quris’s patented Chip-on-Chip technology. Dual-headquartered in Boston and Israel and backed by strategic biotech and big data investors, Quris is led by a proven team of AI and medical research powerhouses who are already preparing its lead discovery for clinical trials. For more information, visit www.quris.ai.